What is normal pressure hydrocephalus? What to know about Billy Joel's condition as he cancels tour
The brain disorder that forced Billy Joel to cancel his concert tour can cause trouble walking and thinking straight — but is often treatable and can even be reversed, doctors said.
A post on the 76-year-old singer's Instagram on Friday said that he was recently diagnosed with normal pressure hydrocephalus and that concert performances exacerbated problems with his 'hearing, vision, and balance.'
The condition is relatively uncommon, according to the Cleveland Clinic, affecting 'about 5.9% of people over 80.'
It's most commonly diagnosed in older adults, usually showing up around age 70.
The human body is constantly trying to keep a steady level of cerebrospinal fluid to cushion the brain and spinal cord, either by making more or absorbing it.
That fluid tends to take up a little more space in older adults because brain volume shrinks as a normal part of the aging process, said Dr. Wajd Al-Holou, a neurosurgeon at the University of Michigan Health.
"But what happens in normal pressure hydrocephalus is an abnormal buildup of fluid that causes brain dysfunction because of the pressure it's putting on the brain," he said.
Patients are often diagnosed after they see a doctor because they — or a family member — are concerned they might be developing dementia, which is also more common as people age.
Memory loss, bladder control issues and trouble walking are also common. Patients can have trouble lifting their feet, putting them at risk for stumbling and falling.
Doctors often learn about normal pressure hydrocephalus and its three hallmark symptoms with this catchphrase: 'wet, wobbly and weird,' said Dr. Vikram Udani, a neurosurgeon in private practice in San Diego.
"The 'weird' is the cognitive issue, typically things like memory problems or confusion, and the 'wobbly' stands for gait instability," he said. "The 'wet' is the urinary incontinence."
Brain imaging, either a CT scan or an MRI, is generally used to look for the buildup of fluid, as well as a variety of neurological testing.
Doctors may also do what's called a lumbar puncture to drain the excess fluid. If the person's symptoms improve, the condition is often diagnosed as normal pressure hydrocephalus, or NPH.
Udani said no one knows what causes the condition, but added that it's highly unlikely that loud music or concert touring would trigger NPH.
It can look like dementia, but there's a key difference: normal pressure hydrocephalus is treatable and in many cases reversible if it's caught early.
Commonly, neurosurgeons implant a ventriculoperitoneal shunt, or tube, into the brain that helps drain the fluid buildup into another part of the body, like the abdomen. The patient then essentially pees the excess fluid out, Udani said.
A drug called acetazolamide can also be used, as it may help the body decrease the level of fluid on its own. The medicine doesn't work for everyone, Al-Holou said.
It was unclear Friday what kind of treatment Joel would receive. His social media post said that the singer 'is undergoing specific physical therapy,' but did not give details.
That kind of therapy is usually given, doctors said, to help patients regain balance.
Any treatment is more effective if a diagnosis is made quickly. If the condition goes on too long unchecked, it could lead to permanent brain damage, Al-Holou said.
If a person seems to be experiencing early signs such as troublesome memory loss and difficulty walking, 'they should see a primary care physician or neurologist to investigate further,' he said.
This article was originally published on NBCNews.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Health Line
15 hours ago
- Health Line
Ask the Expert: Should I have Biomarker Testing – and Would it Help?
Biomarker testing in colorectal cancer can help assess inherited risk and identify characteristics that may influence the disease's growth, spread, and response to treatment. Colorectal cancer (CRC) starts in the colon or rectum of the large intestine. Your doctor may refer to it as 'colon cancer' or 'rectal cancer,' depending on where the cancer develops first, but both of these diagnoses are included under the banner of CRC. CRC is treatable, and biomarker testing is a part of precision medicine in your comprehensive treatment plan. Biomarker testing in CRC can help detect cancer in its earliest, most treatable stages. It can also provide important details about cancer after a diagnosis that influence treatment and outcomes. Dr. Smitha Krishnamurthi, a gastrointestinal oncology specialist with the Cleveland Clinic, talks with Healthline about biomarker testing and who it's recommended for. What is biomarker testing? Biomarker testing refers to testing of the colorectal cancer to find out if there are certain changes in the cancer's genes and proteins that could impact prognosis [outlook] and treatment. What are the most common biomarkers, and what do they show? Biomarkers in CRC measure a variety of different biological processes and states. Each biomarker provides important details about the cancer's growth, spread, or treatment response. DNA mismatch repair Hospital pathology labs now commonly test all initial biopsies or surgical specimens of colorectal cancer for the presence of DNA mismatch repair proteins. This is done via immunohistochemistry (IHC) staining of the slides to look for [the] expression of four mismatch repair proteins: MLH1, PMS2, MSH2, and MSH6. If one or two of these proteins are missing, then the cancer has deficient DNA mismatch repair. Microsatellite instability (MSI) This is a polymerase chain reaction (PCR) or next-generation sequencing (NGS) test [that looks] for abnormalities in microsatellite regions of the cancer DNA. The test can be done on a tumor specimen or blood (liquid biopsy). Microsatellites are short, repeated sequences of DNA. If the cancer has [atypical] DNA mismatch repair, errors will appear in microsatellite regions of DNA in the form of missing bases or extra bases added to the DNA sequence. RAS gene mutations (mutations in KRAS and NRAS genes) This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). RAS is a very important oncogene, meaning that it is a gene that, when mutated, drives cancer cell proliferation and survival. Mutations in RAS genes are found in up to 50% of colorectal cancers. BRAF V600E gene mutation This testing can be performed by PCR or NGS testing of the tumor or NGS testing of blood (liquid biopsy). The BRAF V600E protein can also be detected by IHC. BRAF is another oncogene, so when it is mutated, it leads to cancer cell proliferation and survival. BRAF V600E mutations occur in about 8% to 10% of colorectal cancers and are more common in right-sided cancers. HER2 protein overexpression by IHC or gene amplification by NGS HER2 is another oncogene — gene amplification leads to [the] overexpression of the HER2 protein. Overexpression of HER2 leads to increased signaling via the epidermal growth factor receptor pathway, leading to cancer cell proliferation and survival. PIK3CA PIK3CA is another oncogene. Mutations in PIK3CA and a related gene, PIK3R1, lead to cancer cell proliferation and survival. Mutations in PIK3CA and PIK3R1 are typically found via NGS. PTEN PTEN is a tumor suppressor gene, [which typically] suppresses cancer growth. When the PTEN gene is mutated, the protein is not expressed, and that leads to [the] proliferation of cancer. PTEN gene mutations are typically found via NGS. Who should have biomarker testing done? All patients with colorectal cancer should have testing of their cancer for DNA mismatch repair (or microsatellite instability) soon after diagnosis. This is important for patients with cancers of all stages. Patients with early stage colorectal cancer should have testing of their cancers for mutations in PIK3CA, PTEN, and PIK3R1 by the time they finish adjuvant treatment or after surgery if [they're] not having adjuvant treatment. Patients with metastatic colorectal cancer should have next-generation sequencing of the cancer soon after diagnosis, as the results may impact the initial systemic treatment. The NGS results are also useful for identifying clinical trial eligibility. Comorbidities will not affect the results of these biomarkers, so they should not affect the timing and decision making about ordering these tests. How does biomarker testing help the treatment and outcome of a diagnosis? Biomarkers can impact your treatment choices and outcomes. They can help doctors decide which medications will be the most effective, identify inherited features in cancer, and determine if adjuvant or additional therapies would improve outcomes. Immunotherapy responsiveness It is critical to know if a cancer has deficient DNA mismatch repair (dMMR) or high microsatellite instability (MSI-H) because these cancers can respond dramatically to immunotherapy in the early stage and metastatic settings. For example, patients with rectal cancer that is dMMR or MSI-H may have a complete clinical response with immunotherapy and may be able to avoid radiation and surgery. Thus, this testing needs to be done early, before treatment starts. Identifying Lynch syndrome Another important reason for testing for dMMR or MSI-H is to identify cancers caused by Lynch syndrome. Lynch syndrome is the most common type of inherited colorectal cancer and is caused by germline mutations in the genes that code for the DNA mismatch repair proteins or in another related gene called EPCAM. Most cancers with deficient mismatch repair or MSI-H are not caused by Lynch syndrome and occur sporadically. We don't want to miss patients with Lynch syndrome, however, because they can benefit from counseling about [the] prevention of Lynch syndrome-related cancers such as uterine cancer, ovarian cancer, and gastric cancer, in addition to colorectal cancer. When a patient is diagnosed with Lynch syndrome, family members can then be tested to see if they have Lynch syndrome. Recommendations for cancer screening at early stages are made for individuals with Lynch syndrome, and early screening can be lifesaving. Identifying treatment resistance Mutations in KRAS and NRAS make cancers resistant to anti-epidermal growth factor receptor therapy. Cancers with KRAS G12C mutations can be treated with a regimen that targets this mutation (adagrasib plus cetuximab or sotorasib plus panitumumab). There are also many clinical trials now studying RAS gene inhibitors in patients with metastatic colorectal cancer that have been previously treated. Cancers with BRAF V600E tend to be aggressive and less sensitive to chemotherapy. There is a Food and Drug Administration (FDA)-approved regimen targeting BRAF V600E (encorafenib plus cetuximab) in metastatic colorectal cancer that improves survival when added to first-line FOLFOX chemotherapy. It also improves survival as a second-line treatment after chemotherapy. Greater response to targeted and adjuvant therapy Metastatic colorectal cancers that demonstrate [the] overexpression or gene amplification of HER2 can be treated with a targeted regimen of tucatinib plus trastuzumab after initial chemotherapy. Another targeted treatment available for metastatic colorectal cancers that overexpress HER2 by IHC is trastuzumab deruxtecan. Patients with early stage colorectal cancer with mutations in the PIK3CA, PIK3R1, or PTEN genes should be treated with aspirin 160 milligrams daily for 3 years after adjuvant therapy or after surgery if [they're] not having adjuvant therapy. The ALASCCA trial, presented at ASCO GI [American Society of Clinical Oncology – Gastrointestinal Cancer] in 2025, compared a placebo to aspirin in this patient population and found that aspirin significantly lowered the rate of cancer recurrence at 3 years. This is rather new data. Oncologists are starting to order NGS testing for patients with early stage cancers in order to obtain this biomarker information. What should you ask your doctor? It's always OK to ask your doctor about biomarker testing and what it means for you. Important questions to consider include: Is my cancer dMMR/MSI-H? Am I a candidate for immunotherapy? Patients with early stage colorectal cancer should ask if aspirin therapy will be recommended based on biomarker testing. Patients with metastatic colorectal cancer should ask for the results of RAS/BRAF/HER2 testing and overall NGS testing results.
Yahoo
a day ago
- Yahoo
‘She always said, 'I'm going to be famous, dad'': Teen dies after viral TikTok ‘dusting' challenge
The parents of a 19-year-old who dreamed of fame and died after trying the TikTok 'dusting' trend are warning others about its deadly risks. Renna O'Rourke and her boyfriend DoorDashed aerosol keyboard cleaner to her parents' Tempe, Arizona, home without her mother's knowledge, Dana O'Rourke told 12 News. The dusting trend, also known as chroming or huffing, involves inhaling common household cleaners to get high for views online. The sensation causes brief euphoria but can cause instant, fatal damage, often due to heart failure, according to the Cleveland Clinic. After inhaling the keyboard cleaner, Renna went into cardiac arrest, spent a week unconscious in the intensive care unit, and then was declared brain-dead. Renna's parents described their late daughter as 'vivacious and caring and loyal.' Her father, Aaron O'Rourke, told 12 News that Renna loved to sing and lit up every room with her smile and laughter. 'She always said, 'I'm going to be famous, dad. Just you watch. I'm going to be famous,' and unfortunately, this is not under the most optimal of circumstances,' Aaron O'Rourke, told the outlet.. Despite the less-than-ideal circumstances, the O'Rourke family is now working to honor Renna by spreading the word about the dangers of huffing for teens and parents. 'There's no ID required. It's odorless. It's everything kids look for. They can afford it, they can get it, and it doesn't show in mom and dad's drug test,' Dana O'Rourke told AZ Family about access to the trendy chemicals. She added, 'Don't take your kid's word for it. Dig deep. Search their rooms. Don't trust — and that sounds horrible, but it could save their life.' A GoFundMe started to help the O'Rourke family with hospital bills, burial and therapy costs, and to spread awareness about huffing has surpassed its $5,000 goal and sits at over $9,000 at the time of publication.
Yahoo
2 days ago
- Yahoo
Barry Manilow heartbroken by Billy Joel's health crisis
Barry Manilow's heart "broke" when he heard about Billy Joel's health crisis. The veteran musician was forced to cancel all of his tour dates for the rest of the year after he was diagnosed with a rare brain condition called Normal Pressure Hydrocephalus (NPH), which is caused by a build-up of fluid in the brain, and now Manilow has admitted he feels terrible about seeing the Piano Man go through such a tough time. He told Billboard: "Oh, it's so horrible, so horrible. It just broke my heart when I heard about Billy Joel. I'm such a fan of his work. I really hope he's able to get back to it." Manilow went on to admit there aren't many of his contemporaries still performing. He said: "It's like: 'What? Am I the only one left?' It's Billy Joel, and Elton [John] is not well and Rod [Stewart] and Neil [Diamond]. Diana Ross is still in great shape, I think. "There must be only a handful of people in my world that are still there. "I'm still healthy. I'm strong and I've still got my voice and my energy. The night I can't hit the F natural on Even Now, that's the night I throw in the towel. But I can still do it." Joel recently axed all of his tour dates - including 17 dates in North America and England - but reports suggest he has no plans to retire despite the diagnosis. Announcing the news on social media, a statement from Joel's team read: "Billy Joel has announced that he will be cancelling all scheduled concerts following a recent diagnosis of Normal Pressure Hydrocephalus (NPH). This condition has been exacerbated by recent concert performances, leading to problems with hearing, vision and balance. "Under his doctor's instructions, Billy is undergoing physical therapy and has been advised to refrain from performing during this recovery period. Billy is thankful for the excellent care he is receiving and is fully committed to prioritising his health. "He is grateful for the support from fans during this time and looks forward to the day when he can once again take the stage." Billy added his own message to fans, saying: "I'm sincerely sorry to disappoint our audience, and thank you for understanding."